Hoffmann-La Roche: Leukemia, Lymphocytic, Chronic, B-Cell trials

The registry lists 48 Leukemia, Lymphocytic, Chronic, B-Cell studies with Hoffmann-La Roche as lead sponsor. 1 are open to participants now and 28 have results posted.

Phase 1 10Phase 2 15Phase 3 10Phase 4 3No phase 12(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic LeukemiaRecruitingNCT05091424Phase 1
• A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 MutationCompletedNCT04285567Phase 3Results posted
• A Study of Rituximab (MabThera) in Participants With Chronic Lymphocytic Leukemia (CLL)CompletedNCT02533401Phase 2Results posted
• A Study of Obinutuzumab + Bendamustine (BG) in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL)CompletedNCT02320487Phase 2Results posted
• Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic LeukemiaCompletedNCT02242942Phase 3Results posted
• A Study Evaluating the Efficacy of Obinutuzumab and Bendamustine Treatment in Participants With Refractory or Relapsed Chronic Lymphocytic LeukemiaCompletedNCT02071225Phase 2Results posted
• CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 2)CompletedNCT02053610Phase 3Results posted
• CHAIROS Study A Study of MabThera/Rituxan (Rituximab) Maintenance Therapy in Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Naive to ChemotherapyCompletedNCT02013817Phase 2Results posted
• A Study to Evaluate the Benefit of Venetoclax Plus Rituximab Compared With Bendamustine Plus Rituximab in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)CompletedNCT02005471Phase 3Results posted
• CLL11: A Study of Rituximab With Chlorambucil or Chlorambucil Alone in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1b)CompletedNCT01998880Phase 3Results posted
• A Safety and Efficacy Study of Obinutuzumab Alone or in Combination With Chemotherapy in Participants With Chronic Lymphocytic LeukemiaCompletedNCT01905943Phase 3Results posted
• An Expanded Access, Open-Label Study of Obinutuzumab (GA101) Plus Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic LeukemiaCompletedNCT01868893Phase 2Results posted
• A Study of Rituximab (MabThera) in Combination With Chemotherapy in Participants With CD20-Positive B-Cell Chronic Lymphocytic LeukemiaCompletedNCT01609023Results posted
• A Study Comparing Obinutuzumab (RO5072759; GA101) 1000 Milligram (mg) Versus 2000 mg in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL) (GAGE)CompletedNCT01414205Phase 2Results posted
• A Study of Obinutuzumab (GA101; RO5072759) in Combination With Chemotherapy in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL) (GALTON)CompletedNCT01300247Phase 1Results posted
• A Study to Compare Subcutaneous Versus Intravenous MabThera (Rituximab) in Combination With Chemotherapy in Patients With Chronic Lymphocytic LeukemiaCompletedNCT01292603Phase 1Results posted
• A Study to Compare Mabthera (Rituximab), Fludarabine and Cyclophosphamide to Mabthera and Chlorambucil in Participants With Chronic Lymphocytic Leukemia and Unfavorable Somatic StatusTerminatedNCT01283386Phase 4Results posted
• A Study of Rituximab in Combination With Fludarabine and Cyclophosphamide in Participants With Chronic Lymphocytic Leukemia and Favorable Somatic StatusTerminatedNCT01271010Phase 4Results posted
• A Study of MabThera/Rituxan (Rituximab) in Combination With Fludarabine And Cyclophosphamide as Primary Therapy in Elderly Patients With Chronic Lymphocytic LeukemiaCompletedNCT01263704Phase 2Results posted
• A Study on Rituximab (MabThera) in Participants With Chronic Lymphocytic Leukemia (CLL)CompletedNCT01178086Results posted
• A Study of MabThera Added to Bendamustine or Chlorambucil in Patients With Chronic Lymphocytic Leukemia (MaBLe)CompletedNCT01056510Phase 4Results posted
• CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1a)CompletedNCT01010061Phase 3Results posted
• A Proof of Concept Study of the Safety, Tolerability, and Efficacy of Avastin (Bevacizumab) in Patients With Chemo-naive Chronic Lymphocytic LeukemiaCompletedNCT00754650Phase 2Results posted
• A Study of MabThera (Rituximab) Plus Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia.CompletedNCT00738374Phase 2Results posted
• A Study to Assess the Effect of Maintenance Treatment With Rituximab Versus No Treatment in Participants With Progressive B-Cell Chronic Lymphocytic Leukemia (CLL)CompletedNCT00718549Phase 3Results posted
• A Study to Assess the Efficacy of Rituximab (MabThera) in First Line Treatment of Chronic Lymphocytic Leukemia (CLL)CompletedNCT00545714Phase 2Results posted
• A Study of MabThera (Rituximab) Plus Chlorambucil in Participants With Chronic Lymphocytic Leukemia.CompletedNCT00532129Phase 2Results posted
• Fludarabine and Cyclophosphamide With or Without Rituximab in Patients With Previously Untreated Chronic B-Cell Lymphocytic LeukemiaCompletedNCT00281918Phase 3Results posted
• FCR Versus FC Alone in the Treatment of Chronic Lymphocytic Leukemia (CLL) in Relapsed PatientsCompletedNCT00090051Phase 3Results posted
• A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-treatment PeriodActive, not recruitingNCT06524375Phase 2
• Observational Study to Monitor Safety and Effectiveness of Obinutuzumab in Follicular Lymphoma or Previously Untreated Chronic Lymphocytic LeukemiaCompletedNCT03374137
• An Observational Study of MabThera Subcutaneous (SC) Safety in Participants With Non-Hodgkin's Lymphoma (NHL) or Chronic Lymphocytic Leukemia (CLL)CompletedNCT03289182
• Observational Study: Safety and Effectiveness of Obinutuzumab in Chronic Lymphocytic Leukemia in ArgentinaCompletedNCT03059251
• A Study of Obinutuzumab Evaluating Efficacy, Safety and Cost of Disease Management in Participants With Chronic Lymphocytic Leukemia and ComorbiditiesCompletedNCT02915224
• A Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)CompletedNCT02500407Phase 1/2
• Rituximab in Combination With Fludarabine and Cyclophosphamide in Patients With Chronic Lymphocytic LeukemiaCompletedNCT02461316
• A Study Evaluating the Safety of Tocilizumab in Addition to Standard of Care Premedication Given Before Obinutuzumab + Chlorambucil in Participants With Untreated B-Cell Chronic Lymphocytic Leukemia (B-CLL) and ComorbiditiesTerminatedNCT02336048Phase 1
• An Observational Study Examining the Effect of Added MabThera Therapy in Patients With Untreated Chronic Lymphocytic LeukemiaCompletedNCT02080884
• A Study of Venetoclax in Combination With Obinutuzumab in Participants With Chronic Lymphocytic LeukemiaCompletedNCT01685892Phase 1
• A Study of Venetoclax in Combination With Bendamustine + Rituximab or Bendamustine + Obinutuzumab in Participants With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia (CLL)CompletedNCT01671904Phase 1
• An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Relapsing or Refractory Chronic Lymphocytic LeukemiaCompletedNCT01488162
• An Observational Study on The Health Related Quality of Life in Patients With Chronic Lymphocytic LeukaemiaCompletedNCT01395615
• A Study of Escalating Doses of Polatuzumab Vedotin in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma and Chronic Lymphocytic Leukemia and Polatuzumab Vedotin in Combination With Rituximab in Participants With Relapsed or Refractory B-Cell Non-Hodgkins LymphomaCompletedNCT01290549Phase 1
• An Observational Study on the Safety Profile of MabThera/Rituxan (Rituximab) in Combination With Chemotherapy in Patients With B Cell-lineage Chronic Lymphocytic Leukaemia (MABERYC)CompletedNCT01224093
• A Study of the Safety and Pharmacokinetics of Escalating Doses of DCDT2980S in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia And DCDT2980S in Combination With Rituximab in Patients With Relapsed or Refractory B-Cell Non Hodgkin's LymphomaCompletedNCT01209130Phase 1
• A Study of ABT-263 in Combination With Dose-Intensive Rituximab, or Dose-Intensive Rituximab Alone, in Previously Untreated Patients With B-Cell, Chronic Lymphocytic Leukemia (CLL)CompletedNCT01087151Phase 2
• An Observational Study on Infusion-related Adverse Events at Administration of MabThera (Rituximab) in Patients With Chronic Lymphocytic LeukemiaCompletedNCT01072240
• A Trial of the Safety of Escalating Doses of PRO131921 in Patients With Relapsed or Refractory Chronic Lymphocytic LeukemiaTerminatedNCT00496132Phase 1/2